+82.7%
MRVL vs MRNA
+945.0%
-862.3%
-49.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.1% | +13.1% | -20.2% | -8.0% |
| 7D | -36.5% | +20.6% | -57.1% | -37.4% |
| 30D | -41.1% | +27.1% | -68.2% | -42.2% |
| 3M | -26.9% | +353.4% | -380.3% | -38.6% |
| 6M | -2.3% | +446.3% | -448.6% | -21.5% |
| YTD | +88.4% | +776.2% | -687.8% | +45.8% |
| 1Y | +82.7% | +987.9% | -905.2% | +33.5% |
| All | +82.7% | +945.0% | -862.3% | +33.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling